Foamix Pharmaceuticals (FOMX) Set to Announce Quarterly Earnings on Monday

Foamix Pharmaceuticals (NASDAQ:FOMX) is set to issue its quarterly earnings data after the market closes on Monday, February 19th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.03). The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.90 million. Foamix Pharmaceuticals had a negative return on equity of 54.81% and a negative net margin of 1,439.32%. The business’s quarterly revenue was down 64.6% compared to the same quarter last year. During the same period last year, the business earned ($0.19) EPS. On average, analysts expect Foamix Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) opened at $6.20 on Monday. The company has a market cap of $232.08, a P/E ratio of -3.85 and a beta of 1.68. Foamix Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $11.11.

In other news, insider Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $6.05, for a total transaction of $30,250.00. Following the sale, the insider now directly owns 16,271 shares in the company, valued at approximately $98,439.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 20,000 shares of company stock worth $125,400 over the last quarter.

FOMX has been the subject of several recent analyst reports. HC Wainwright set a $12.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Finally, Guggenheim began coverage on Foamix Pharmaceuticals in a research note on Tuesday, December 5th. They set a “buy” rating and a $8.00 target price on the stock.

ILLEGAL ACTIVITY WARNING: “Foamix Pharmaceuticals (FOMX) Set to Announce Quarterly Earnings on Monday” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply